Quinagolide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Quinagolide
Quinagolide: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Quinagolide, so there is currently no new predicted indication. The drug’s own recorded uses are listed below; for this drug the list is empty.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 0 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13982X | Norprolac | Tablet 75 micrograms (as hydrochloride) | Valid |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Points from the data compiled for this report:
- The literature contains a case report of mania after long-term quinagolide use (PMID 17888817), and dopamine agonists may cause neuropsychiatric adverse effects.
- Dopamine agonists are more often associated with somnolence or sleep disturbance than with improved sleep.
- No drug interaction records were found.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.